RANDALL BALL: Open Payments
NPI 1972567451 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,245 in 63 payments from 26 companies in 2025. Trend: 2023 $0 · 2024 $1,137 · 2025 $1,245
Food & beverage: $1,245
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $152 |
| Merck Sharp & Dohme LLC | 7 | $135 |
| ABBVIE INC. | 5 | $105 |
| AstraZeneca Pharmaceuticals LP | 5 | $92 |
| Janssen Biotech, Inc. | 3 | $81 |
| Astellas Pharma US Inc | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $51 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Incyte Corporation | 2 | $47 |
Products named: KEYTRUDA, VENCLEXTA, RYBREVANT, KISQALI, FRUZAQLA, TAGRISSO, JAKAFI, Lenvima.
Industry payments across KY — which companies pay providers there.
